Erbitux 5 mg/mL solution for infusion clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
This study looks at a new combination treatment for a specific type of advanced lung cancer that hasn't been treated before. It aims to see how safe and effective the new treatment, made up of two drugs, is for patients with a particular gene change.
For: Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationItaly · Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
SLURP; A phase 2 intervention study: Detection of early esophageal neoplastic lesions by quantified fluorescence molecular endoscopy using oral and topical administration of bevacizumab-800CW and cetuximab-800CW
This study is looking at a new way to find early changes in the food pipe, especially in people with a condition called Barrett's oesophagus. It uses special glowing liquids, given by mouth, to help doctors see these changes more clearly during a camera examination.
For: Barrett's esophagusNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study)
This study compares a new drug, xevinapant, plus standard treatment for an advanced form of head and neck cancer. Researchers want to see if adding xevinapant helps patients live longer without their cancer getting worse, compared to the standard treatment alone.
For: Locally advanced squamous cell carcinoma of the head and neckFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
This study looks at a new way to treat advanced head and neck cancer in older patients not suitable for standard chemotherapy. It combines a special gel (NBTXR3) with usual radiotherapy, sometimes with another drug (Cetuximab, also known as Erbitux), to see if it helps patients live longer without their cancer getting worse.
For: Locally Advanced Head & Neck Squamous Cell CarcinomaCzechia · Greece · Germany - AuthorisedTherapeutic exploratory (Phase II)
REFLECT; Real-time targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the head and neck
This study looks at a new way to find hidden head and neck cancers using special glow-in-the-dark technology during endoscopy. It aims to see if this method, along with a drug called Erbitux, can help doctors locate the main cancer when only a related lump (metastasis) is found.
For: Unknown primary tumour of the head and neckNetherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study looks at a new drug, AZD0022, for people with certain types of lung, bowel, and pancreatic cancer. Doctors want to see if it's safe, how the body handles it, and if it can help shrink tumours, both on its own and with other cancer drugs.
For: Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal AdenocarcinomaBelgium · Poland · Italy